Journal:Acta Cryst F:S2053230X24010094
From Proteopedia
(Difference between revisions)
| Line 7: | Line 7: | ||
This study presents the high-resolution crystal structure of the intracellular domain of T<scene name='10/1060550/Fig_02/1'>GFβR1 in complex with the competitive inhibitor SB505124</scene>. Our findings provide detailed insights into this complex's molecular interactions and structural configuration, elucidating the mechanisms by which SB505124 inhibits TGFβR1 activity. These insights are significant for understanding the regulation of TGF-β signaling, a pathway critically involved in cancer biology. | This study presents the high-resolution crystal structure of the intracellular domain of T<scene name='10/1060550/Fig_02/1'>GFβR1 in complex with the competitive inhibitor SB505124</scene>. Our findings provide detailed insights into this complex's molecular interactions and structural configuration, elucidating the mechanisms by which SB505124 inhibits TGFβR1 activity. These insights are significant for understanding the regulation of TGF-β signaling, a pathway critically involved in cancer biology. | ||
The manuscript highlights several key points: | The manuscript highlights several key points: | ||
| - | 1. Structural Insights: We reveal the atomic-level interactions between TGFβR1 and SB505124, offering a comprehensive view of how this inhibitor binds to and affects the receptor's conformation. | + | 1. Structural Insights: We reveal the atomic-level <scene name='10/1060550/Fig_02/2'>interactions between TGFβR1 and SB505124</scene>, offering a comprehensive view of how this inhibitor binds to and affects the receptor's conformation. |
2. Regulatory Mechanisms: Our structural analysis sheds light on the functional implications of SB505124 binding, particularly its role in disrupting TGF-β signaling pathways, which are often deregulated in various cancers. | 2. Regulatory Mechanisms: Our structural analysis sheds light on the functional implications of SB505124 binding, particularly its role in disrupting TGF-β signaling pathways, which are often deregulated in various cancers. | ||
3. Therapeutic Potential: Based on our structural findings, we discuss the potential of SB505124 as a therapeutic agent in cancer treatment, providing a foundation for future drug development efforts targeting TGFβR1. | 3. Therapeutic Potential: Based on our structural findings, we discuss the potential of SB505124 as a therapeutic agent in cancer treatment, providing a foundation for future drug development efforts targeting TGFβR1. | ||
Revision as of 12:59, 22 October 2024
| |||||||||||
This page complements a publication in scientific journals and is one of the Proteopedia's Interactive 3D Complement pages. For aditional details please see I3DC.
